![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The Phase 1 study is designed to evaluate the safety and tolerability of EMP-01 (3,4-methylenedioxymethamphetamine) in participants, as well as assess the usability and acceptability of the IDEA-1 app in delivering “set and setting” content to participants.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: EMP-01
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: ATAI Life Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022